Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carotid Artery Diseases | 7 | 2020 | 97 | 2.100 |
Why?
|
| Dyslipidemias | 4 | 2017 | 109 | 1.790 |
Why?
|
| Hypolipidemic Agents | 6 | 2018 | 102 | 1.620 |
Why?
|
| Lipids | 4 | 2014 | 269 | 1.610 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2020 | 378 | 1.420 |
Why?
|
| Atherosclerosis | 5 | 2016 | 243 | 1.120 |
Why?
|
| Coronary Artery Disease | 4 | 2021 | 350 | 1.070 |
Why?
|
| Carotid Arteries | 4 | 2018 | 127 | 1.060 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2020 | 38 | 0.830 |
Why?
|
| HIV Infections | 2 | 2020 | 772 | 0.740 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2018 | 54 | 0.720 |
Why?
|
| Cause of Death | 1 | 2020 | 277 | 0.680 |
Why?
|
| Heart Sounds | 1 | 2017 | 1 | 0.620 |
Why?
|
| American Heart Association | 1 | 2017 | 92 | 0.590 |
Why?
|
| Primary Prevention | 1 | 2017 | 85 | 0.580 |
Why?
|
| Myocardial Contraction | 1 | 2017 | 244 | 0.560 |
Why?
|
| Cyclin D1 | 1 | 2016 | 83 | 0.560 |
Why?
|
| Pericardium | 1 | 2016 | 65 | 0.540 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 157 | 0.530 |
Why?
|
| Guideline Adherence | 1 | 2017 | 223 | 0.530 |
Why?
|
| Foramen Ovale, Patent | 1 | 2015 | 18 | 0.520 |
Why?
|
| Anticholesteremic Agents | 2 | 2016 | 137 | 0.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1197 | 0.480 |
Why?
|
| Carotid Stenosis | 2 | 2012 | 112 | 0.480 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 137 | 0.480 |
Why?
|
| Adipose Tissue | 1 | 2016 | 240 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2012 | 3352 | 0.470 |
Why?
|
| Azetidines | 2 | 2016 | 36 | 0.460 |
Why?
|
| Thrombosis | 2 | 2015 | 296 | 0.450 |
Why?
|
| Cardiovascular Diseases | 3 | 2015 | 827 | 0.450 |
Why?
|
| Heart Diseases | 1 | 2015 | 290 | 0.440 |
Why?
|
| Coronary Stenosis | 1 | 2012 | 39 | 0.430 |
Why?
|
| Jejunum | 1 | 2012 | 79 | 0.430 |
Why?
|
| Intestinal Absorption | 1 | 2012 | 124 | 0.420 |
Why?
|
| Heart Ventricles | 1 | 2017 | 760 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 581 | 0.410 |
Why?
|
| MicroRNAs | 1 | 2016 | 534 | 0.390 |
Why?
|
| Cholesterol, HDL | 4 | 2017 | 165 | 0.390 |
Why?
|
| Disease Progression | 4 | 2020 | 1531 | 0.370 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1034 | 0.360 |
Why?
|
| Cholesterol, LDL | 6 | 2018 | 222 | 0.340 |
Why?
|
| Blood Glucose | 1 | 2012 | 873 | 0.330 |
Why?
|
| Hypertension | 1 | 2017 | 1141 | 0.330 |
Why?
|
| Middle Aged | 14 | 2020 | 25017 | 0.320 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2006 | 4 | 0.300 |
Why?
|
| Trypanosoma cruzi | 1 | 2006 | 7 | 0.300 |
Why?
|
| Humans | 24 | 2021 | 86601 | 0.280 |
Why?
|
| Lipoproteins, HDL | 1 | 2006 | 96 | 0.280 |
Why?
|
| Male | 15 | 2020 | 40956 | 0.250 |
Why?
|
| Niacin | 4 | 2016 | 37 | 0.240 |
Why?
|
| Risk Factors | 4 | 2020 | 5416 | 0.230 |
Why?
|
| Treatment Outcome | 6 | 2018 | 7988 | 0.230 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2018 | 261 | 0.220 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 364 | 0.210 |
Why?
|
| Biomarkers | 4 | 2018 | 1718 | 0.210 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 3636 | 0.210 |
Why?
|
| Heart Transplantation | 1 | 2006 | 705 | 0.190 |
Why?
|
| Incidence | 3 | 2015 | 1576 | 0.190 |
Why?
|
| Cell Proliferation | 2 | 2016 | 1578 | 0.180 |
Why?
|
| Time Factors | 4 | 2018 | 5209 | 0.180 |
Why?
|
| Female | 11 | 2020 | 44507 | 0.170 |
Why?
|
| Coronary Angiography | 2 | 2012 | 232 | 0.170 |
Why?
|
| Lipoprotein(a) | 1 | 2018 | 28 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 857 | 0.160 |
Why?
|
| Compliance | 1 | 2017 | 23 | 0.150 |
Why?
|
| Asymptomatic Diseases | 1 | 2017 | 41 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 879 | 0.150 |
Why?
|
| Chest Pain | 1 | 2017 | 42 | 0.150 |
Why?
|
| Heart Failure | 1 | 2006 | 1203 | 0.150 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2016 | 14 | 0.140 |
Why?
|
| Antigens, Nuclear | 1 | 2016 | 25 | 0.140 |
Why?
|
| Melanocytes | 1 | 2016 | 56 | 0.140 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 92 | 0.140 |
Why?
|
| Linear Models | 1 | 2017 | 421 | 0.140 |
Why?
|
| Proprotein Convertases | 1 | 2015 | 26 | 0.140 |
Why?
|
| Adult | 8 | 2018 | 25640 | 0.140 |
Why?
|
| Immunoblotting | 1 | 2016 | 268 | 0.140 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2015 | 20 | 0.130 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2015 | 50 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 999 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2016 | 1169 | 0.120 |
Why?
|
| Cell Cycle | 1 | 2016 | 502 | 0.120 |
Why?
|
| Heptanoic Acids | 2 | 2011 | 72 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1019 | 0.120 |
Why?
|
| Cisplatin | 1 | 2016 | 612 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 266 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2020 | 2767 | 0.110 |
Why?
|
| Nerve Tissue Proteins | 1 | 2016 | 503 | 0.110 |
Why?
|
| Pyrroles | 2 | 2011 | 184 | 0.110 |
Why?
|
| Apoptosis | 2 | 2016 | 1683 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2020 | 2261 | 0.110 |
Why?
|
| Ezetimibe | 1 | 2012 | 35 | 0.110 |
Why?
|
| Simvastatin | 2 | 2016 | 106 | 0.100 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 894 | 0.100 |
Why?
|
| Melanoma | 1 | 2016 | 454 | 0.100 |
Why?
|
| Global Health | 1 | 2013 | 193 | 0.100 |
Why?
|
| Smoking | 1 | 2015 | 609 | 0.100 |
Why?
|
| Cell Line | 1 | 2016 | 2468 | 0.100 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2426 | 0.090 |
Why?
|
| Case-Control Studies | 1 | 2014 | 1804 | 0.090 |
Why?
|
| Age Factors | 1 | 2014 | 1849 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2016 | 1565 | 0.080 |
Why?
|
| Aged | 3 | 2018 | 18402 | 0.070 |
Why?
|
| Carotid Artery, Common | 1 | 2006 | 29 | 0.070 |
Why?
|
| Carotid Artery, Internal | 1 | 2006 | 69 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 261 | 0.060 |
Why?
|
| United States | 1 | 2017 | 6665 | 0.060 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2006 | 159 | 0.060 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2357 | 0.060 |
Why?
|
| Double-Blind Method | 3 | 2018 | 1823 | 0.060 |
Why?
|
| Animals | 3 | 2015 | 26581 | 0.050 |
Why?
|
| Contrast Media | 1 | 2006 | 1077 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1673 | 0.050 |
Why?
|
| Lipid Metabolism | 2 | 2011 | 196 | 0.040 |
Why?
|
| Colestipol | 1 | 2016 | 3 | 0.040 |
Why?
|
| Lovastatin | 1 | 2016 | 29 | 0.040 |
Why?
|
| Luciferases | 1 | 2016 | 118 | 0.030 |
Why?
|
| Hyperlipoproteinemias | 1 | 2015 | 7 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 133 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2015 | 20 | 0.030 |
Why?
|
| Triglycerides | 1 | 2016 | 232 | 0.030 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2015 | 69 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 316 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2015 | 53 | 0.030 |
Why?
|
| Streptokinase | 1 | 1995 | 12 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 273 | 0.030 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 1995 | 12 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2016 | 280 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 145 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2015 | 408 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 782 | 0.030 |
Why?
|
| Adipocytes | 1 | 2015 | 155 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 369 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1995 | 93 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 860 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 547 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 736 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2015 | 460 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1098 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2015 | 230 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 937 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 1995 | 220 | 0.030 |
Why?
|
| Idaho | 1 | 2011 | 7 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2011 | 38 | 0.030 |
Why?
|
| Washington | 1 | 2011 | 48 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 479 | 0.030 |
Why?
|
| Necrosis | 1 | 2011 | 204 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2011 | 4210 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2818 | 0.020 |
Why?
|
| Fibrosis | 1 | 2011 | 203 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2015 | 797 | 0.020 |
Why?
|
| Liver | 1 | 2015 | 1229 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1981 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 930 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 1376 | 0.020 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2007 | 11 | 0.020 |
Why?
|
| Allylamine | 1 | 2007 | 11 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6501 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2270 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1156 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2016 | 3241 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 2216 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1995 | 2207 | 0.020 |
Why?
|
| Mutation | 1 | 2015 | 3967 | 0.020 |
Why?
|
| Mice | 1 | 2015 | 11352 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2705 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1995 | 278 | 0.010 |
Why?
|